Clinical Trial Update: A Study of the Safety of Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior Disorders [Phase 3]

View source ↗

Summary

Phase 3 study reporting on the safety of risperidone in children and adolescents with conduct and other disruptive behavior disorders. The update highlights saf…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Conduct Disorder
• Disruptive Behavior Disorder

Drugs mentioned

• RISPERIDONE (RISPERIDONE)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Disruptive Behavior Disorder | Phase 3 | Status: COMPLETED